![]() |
|
|
My Amedeo
FAQ
Privacy
About
|
For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF |
| Multiple Sclerosis |
|
Free Subscription
1 Arch Phys Med Rehabil |
Retrieve available abstracts of this week’s articles:
HTML format |
| Single Articles |
AMEDEO Multiple Sclerosis is free of charge.
Evidence-Based Cognitive Rehabilitation for Persons with Multiple Sclerosis: An
Updated Systematic Review 2016 to 2024.
Arch Phys Med Rehabil. 2026 May 25:S0003-9993(26)00733.
PubMed
Abstract available
Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on
the risk and clinical outcomes of multiple sclerosis.
BMC Neurol. 2026;26:355.
PubMed
Abstract available
The role of health literacy in medication adherence among people living with
multiple sclerosis: a cross-sectional study in Isfahan, Iran.
BMC Neurol. 2026 May 25. doi: 10.1186/s12883-026-04985.
PubMed
Abstract available
High-efficacy therapy and progression independent of relapse and MRI activity in
multiple sclerosis.
Brain. 2026 May 28:awag175. doi: 10.1093.
PubMed
The skull-meningeal axis: a new window into multiple sclerosis progression.
Brain. 2026 May 28:awag177. doi: 10.1093.
PubMed
Reduced socs2 expression and elevated IL-4/IL-23 levels in multiple sclerosis
patients: Implications for immune dysregulation.
Hum Immunol. 2026;87:111763.
PubMed
Abstract available
Myelin antigen-specific effector CD8+ T cells induce chronic CNS autoimmunity in
a CD4+ T cell-dependent manner.
J Immunol. 2026;215:vkag107.
PubMed
Abstract available
Artificial intelligence for gait and balance in neurological disorders: a scoping
review of clinical applications and technologies.
J Neurol. 2026;273:346.
PubMed
Abstract available
Integrating peripheral immune control and brain health in the multiple sclerosis
continuum.
Lancet. 2026;407:2144-2146.
PubMed
Stephen Hauser: transforming treatment for multiple sclerosis.
Lancet. 2026;407:2163.
PubMed
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in
relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two
multicentre, randomised, double-blind, parallel-group phase 3b trials.
Lancet. 2026;407:2180-2194.
PubMed
Abstract available
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis,
including older patients and those with more advanced disease (ORATORIO-HAND): a
multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
Lancet. 2026;407:2195-2207.
PubMed
Abstract available
Adenotonsillectomy is associated with increased risk and disease activity in
pediatric-onset multiple sclerosis.
Mult Scler. 2026 May 29:13524585261444244. doi: 10.1177/13524585261444244.
PubMed
Abstract available
Prescription drug dispensations 15 years before multiple sclerosis onset: A
matched cohort study, British Columbia, Canada.
Mult Scler. 2026 May 27:13524585261450813. doi: 10.1177/13524585261450813.
PubMed
Abstract available
Phenotyping healthcare use before pediatric-onset multiple sclerosis, including
by sex and age: A matched cohort study.
Mult Scler. 2026 May 22:13524585261445372. doi: 10.1177/13524585261445372.
PubMed
Abstract available
Clinical, structural, and functional MRI features predicting PIRMA at 5-year
follow-up in multiple sclerosis.
Mult Scler. 2026 May 22:13524585261445318. doi: 10.1177/13524585261445318.
PubMed
Abstract available
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent
Long-Term Disability.
Neurology. 2026;106:e218056.
PubMed
Abstract available
Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy
Therapy Decreases Disability in Pediatric Multiple Sclerosis.
Neurology. 2026;106:e218168.
PubMed
Vocational rehabilitation for people with multiple sclerosis: A systematic
scoping review of international evidence.
PLoS One. 2026;21:e0350122.
PubMed
Abstract available
Retinal macrophage-like cell activation and ganglion cell layer thinning are
associated with disability and MRI lesion burden in multiple sclerosis.
PLoS One. 2026;21:e0349679.
PubMed
Abstract available
Thank you for your interest in scientific medicine.